Scott Berry, Founder of Berry Consultants, interviews Professor Craig Ritchie—specialist in brain health and neurodegenerative diseases, Chief Investigator of EPAD (European Prevention of Alzheimer Dementia), and CEO of Scottish Brain Sciences—for a precise analysis of platform trial methodology in Alzheimer’s research.

Regression-to-the-mean offers critical insights for drug development, like sports statistics, emphasizing the importance of understanding data variability across multiple levels of inference.

In this engaging episode of "In the Interim...", host Dr. Scott Berry is joined by Dr. Nick Berry to explore the intriguing parallels between sports and drug development, focusing on the concept of "regression-to-the-mean."

Understanding DSMBs is pivotal in ensuring trial integrity, safety, and success.

In this episode of "In the Interim…", host Dr. Scott Berry is true to the name of the podcast, as he discusses the unblinded world of adaptive clinical trials alongside Dr. Roger Lewis, a renowned expert in both statistical science and clinical medicine.

In this FACTS webinar, the Berry Consultants team unveils FACTS 7.1.1, showcasing important updates to our statistical software for clinical trial design.